Chimeric Therapeutics (ASX:CHM) launches phase 1b glioblastoma trial
27 Jun 2023 – Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses promising results in the company’s lead therapy for glioblastoma, and the timeline for the recently launched Phase 1b trial.
Chimeric Therapeutics (ASX:CHM) launches phase 1b glioblastoma trial Read More »